Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2024 07:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate...
July 30, 2024 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Oversubscribed $175.0 Million Private Placement

BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing...
June 18, 2024 08:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of...
May 30, 2024 08:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Sale of Priority Review Voucher for $108 Million

BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and...
May 06, 2024 16:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. ...
April 23, 2024 15:56 ET | Source: Day One Biopharmaceuticals, Inc.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
February 26, 2024 16:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023...
January 17, 2024 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Two New Appointments to Board of Directors

BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and...
December 19, 2023 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and...
November 17, 2023 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and...